Production (Stage)
Drugs Made In America Acquisition Corp.
DMAA
$10.18
-$0.01-0.10%
NASDAQ
03/31/2025 | |||||
---|---|---|---|---|---|
Total Cash And Short-Term Investments | -35.71% | ||||
Total Receivables | -- | ||||
Inventory | -- | ||||
Prepaid Expenses | 1,847.22% | ||||
Finance Division Loans and Leases Current | -- | ||||
Total Finance Division Other Current Assets | -- | ||||
Other Current Assets | -- | ||||
Total Current Assets | 1,320.00% | ||||
|
|||||
Total Current Assets | 1,320.00% | ||||
Net Property, Plant & Equipment | -- | ||||
Long-term Investments | -- | ||||
Goodwill | -- | ||||
Total Other Intangibles | -- | ||||
Finance Div Loans & Leases LT | -- | ||||
Total Finance Div Other LT Assets | -- | ||||
Total Other Assets | 42,541.17% | ||||
Total Assets | 42,166.98% | ||||
|
|||||
Total Accounts Payable | -- | ||||
Total Accrued Expenses | 71.41% | ||||
Short-term Debt | -90.80% | ||||
Current Portion of Long-Term Debt/Capital Leases | -- | ||||
Finance Division Debt Current | -- | ||||
Total Finance Division Other Current Liabilities | 174.51% | ||||
Total Other Current Liabilities | 174.51% | ||||
Total Current Liabilities | -56.34% | ||||
|
|||||
Total Current Liabilities | -56.34% | ||||
Long-Term Debt | -- | ||||
Short-term Debt | -90.80% | ||||
Capital Leases | -- | ||||
Finance Division Debt Non Current | -- | ||||
Total Finance Division Other Non Current Liabilities | -- | ||||
Total Other Liabilities | -- | ||||
Total Liabilities | 30,059.96% | ||||
|
|||||
Common Stock & APIC | -96.86% | ||||
Retained Earnings | -2,160.54% | ||||
Treasury Stock & Other | -- | ||||
Total Common Equity | -2,831.54% | ||||
|
|||||
Preferred Stock Redeemable | -- | ||||
Preferred Stock Non Redeemable | -- | ||||
Preferred Stock Convertible | -- | ||||
Preferred Stock, Others | -- | ||||
Total Preferred Equity | -- | ||||
|
|||||
Total Common Equity | -2,831.54% | ||||
Total Preferred Equity | -- | ||||
Total Minority Interest | -- | ||||
Total Equity | -2,831.54% | ||||
|